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Abstract
In 2003 the UK National Blood Service introduced a policy of ‘male donor pre-
ference’ which involved women’s plasma being discarded following blood collec-
tion. The policy was based on the view that data relating to the incidence of
Transfusion-Related Acute Lung Injury (TRALI) was linked to transfusion with
women’s plasma. While appearing to treat female donors as equal to male donors,
exclusion criteria operate after donation at the stage of processing blood, thus per-
petuating myths of universality even though only certain ‘extractions’ from women
are retained for use in transfusion. Many women in the UK receive a plasma-
derived product called Anti-D immunoglobulin which is manufactured from pooled
male plasma. This article examines ways in which gender has significance for under-
standing blood relations, and how the blood economy is gendered. In our study of
relations between blood donors and recipients, we explore how gendered bodies
are produced through the discursive and material practices within blood services.
We examine both how donation policies and the manufacturing and use of blood
products produces gendered blood relations.
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This article examines ways in which gender has significance for
understanding blood relations, and how the blood economy is gen-
dered. It has previously been recognised that the wider bioeconomy
is gendered through practices which mobilise women’s reproductive
tissues, for example, oocytes, fetal tissue, embryos and cord blood for
use as sources of stem cells (Kent, 2012; Waldby, 2008; Waldby and
Cooper, 2010). Ova exchange for therapeutic treatment of infertility
has been framed as enabling women to assist others to have children,
but also as reproducing racialised, national ideals (Konrad, 1998;
Nahman, 2006). Although data on organ transplantation have identi-
fied women as comprising the majority of donors, it also reveals that
men are much more likely to become organ recipients (Jindal et al.,
2005). What these and other studies have shown is that bodies have
become more plastic and flexible, with exchanges of biological mate-
rials becoming increasingly associated with new forms of biological
citizenship and capital accumulation (Rose and Novas, 2005). In our
study of relations between blood donors and recipients we explore
how gendered bodies are produced through the discursive and mate-
rial practices within national blood services.
Anthropological studies of the socio-cultural meanings and ethics
of blood donation have drawn attention to the complexities of blood
relations and highlighted diversity across communities within differ-
ing cultural, national, religious and political contexts (Copeman,
2009; Mauss, 1990 [1950]). Titmuss (1970) claimed that the ethical
imperative in whole blood donation through national blood services
should be conceptualised using the notion of the gift relationship
which involved the altruistic donation of blood without financial
reward. This was to be seen as a preferred moral choice underpinned
by the social contract that bound communities together. Titmuss’s
conception of the gift relationship was underpinned by appeals to
universality: it was seen as an important act of social (or biological)
citizenship, promoted on the part of national blood services to pro-
vide both a moral and institutional basis for encouraging blood dona-
tion in an organised manner (Healy, 2006).
A more critical understanding of blood donation and its associa-
tion with concepts of citizenship, solidarity and altruism has since
been developed. Blood donation has been demonstrated to be a
highly politicised issue, especially where tensions have arisen due
to some social groups being excluded as donors. Policies of ‘donor
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deferral’, commonly justified by policy makers on the grounds of
ensuring blood safety, have been controversial and increasingly sub-
ject to critical scrutiny. In practice, the public health objective of
ensuring a safe blood supply and underlying ‘safety logics’ (Hoeyer,
2010) has meant that any claim to universality in blood donation is
contingent. Donor deferrals and exclusions have been instituted by
national blood services for a range of scientific, social and institu-
tional reasons which deserve analysis. Some potential donors are
refused permission to donate for reasons that may vary across state
boundaries, regulatory regimes or cultural mores. Yet such exclu-
sions are frequently obscured by a discourse of universality of blood
donation and under-explored notions of citizenship, as Valentine
(2005: 119) points out: ‘The universality of blood is implicitly, and
sometimes explicitly, equated with a universal possibility of donating
it’, even though exclusions create categories of ‘not quite citizens’.
The gendering of bodies has traditionally rendered women as ‘not
quite citizens’ or at least different kinds of citizens. While the defer-
ral of men who have sex with men (MSM) from becoming donors
has foregrounded links between sexual identity and blood donation
(Martucci, 2010; Valentine, 2005), the connections with gender have
been less well elaborated. Rather, it is commonly assumed, that (het-
erosexual) men and women are equally valued as blood donors, espe-
cially in western blood economies. We argue here that this is far from
the case.
This article focuses primarily on current policy and practices in the
UK. It analyses international blood donation policies, clinical and
scientific literature, draws on a public tour of a major blood process-
ing facility, a field visit to a plasma products manufacturer and inter-
views with transfusion specialists, representatives of patient groups
and the plasma industry as part of a larger project on consent, risk and
safety in UK blood services.1 Such research raised questions about
contemporary practices within blood services and the plasma indus-
try. Why are all women presumed to represent a threat to the safety of
plasma transfusions when not all will become, or will have been,
pregnant? How is gender identity mapped onto discourses of risk,
safety and understandings of pathological bodies, in this context?
Why are men (unless previously transfused), presumed to have low
(normal) antibody levels? Given the uncertainties of the causes
of a particular complication of plasma transfusion, known as
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transfusion-related acute lung injury (TRALI), what political con-
ditions contributed to a strategy of excluding women as plasma
donors for transfusion in the UK and elsewhere? To what extent
have the potential risks of TRALI, associated with transfusion by
female plasma, been prioritised over potential benefits, such as the
claims that cardiac patients transfused with female plasma had bet-
ter outcomes?
With these questions in mind, we conclude that blood relations are
gendered, transfusion science produces gendered bodies and technol-
ogies of plasma fractionation are shaped by gender inequalities. In
order to explore this argument, the article first discusses the signifi-
cance of gender for blood and plasma donation. Then we look at how
gender relations structure the production and use of the plasma-
derived product Anti-D Immunoglobulin (Anti-D Ig) in the treatment
of parturient women to prevent haemolytic disease of the fetus and
newborn (HDFN).
Gender and ‘Risky Bodies’
Feminist analyses have drawn attention to the ways in which gender
inequalities are obscured through the universalising narratives of the
liberal humanist subject and modernist science. From the 1970s
onwards, studies explored aspects of women’s health and elaborated
ways in which contemporary biomedicine perpetuated masculinist
notions of healthy bodies, neglected the specificities of women’s
experience of illness and health, and pathologised pregnancy and
childbirth (see, for example, Martin, 1993). Health services have
been shown to institutionalise discriminatory practices perpetuating
health and social inequalities. Through a focus on embodiment and
lived experience, the gendered aspects of health and illness were
described. Essentialist readings of the gendered body increasingly
became problematised, and understandings of the body as a natura-
lised, biological given were seen as unsatisfactory. Instead, accounts
of the multiple, socio-historical and cultural processes which produce
bodies and bodily difference highlighted the contingent and uncer-
tain, leaky boundaries of bodies (Shildrick, 1997). The regulation,
disciplining and production of bodies through the biomedical
sciences became more clearly recognised as a political project, part
of a new kind of ‘vital politics’ or biopolitics (Rose, 2007). Biopower
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is seen as productive. Following Haraway and others, the entangle-
ment of biology and politics becomes evident, including theories of the
immune system (Martin, 1994), transplantation science (Shildrick,
2008), regenerative medicine (Kent, 2012) and, we argue, transfusion
science. In short, contemporary theorising of gender raises a number of
questions about how gender difference is enacted in blood services
through material and discursive practices.
Transfusion science is a discourse or truth regime which creates
and translates rules into clinical practices and industry standards in
blood services. It underpins not only the organisation and delivery
of such services but also the global plasma products industry. Gen-
dered bodies are both naturalised and made invisible in a discourse
which draws heavily on universalising myths that seek to value blood
and plasma donation as a social and public good, and ties donation to
citizenship and social solidarity. It also assumes that bioavailability
(Cohen, 2005) has equalising effects whereby all donations are
equally valued, despite evidence to the contrary which we will dis-
cuss in more detail later.
Our conceptual approach sees policy and practices within blood
services and the plasma products industry as situating bodies in dif-
ferent ways – MSM donors, donors with a history of transfusion,
donor bodies at risk of variant Creutzfeldt-Jakob Disease (vCJD),
female and male donors, and racialised bodies. Blood services and
the plasma products industry produce difference through the devel-
opment of categories for sorting, screening, testing, matching and
evaluating donor and recipient bodies. White male donor bodies –
symbolising the typical blood donor for national blood services –
have come to be viewed as superior sources of blood and plasma
products.
In the context of meeting increasing demand for blood, scarcity
has been an enduring problem for blood services. Attracting a loyal
population of repeat donors who give blood on a regular basis is
important to address this problem and enhance blood safety (Bonig
et al., 2012). There is a significant literature which has examined the
motivations and behaviours of donor populations with a view to
understanding how best to retain them (Masser et al., 2008). Drawing
attention to the numbers of women ineligible to become donors, and
evidence that women are less likely to become donors, Healy (2000)
sees organisational and cultural factors, rather than individual
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motivations, as shaping donor populations. The typical blood donor
in western blood economies is most commonly male, white and edu-
cated, aged in their 30s, with above average occupational level and
income (Piliavin and Callero, 1991), and more likely to be involved
in civic engagement activities (Alessandrini, 2007).
As discussed previously (Farrell, 2012), techniques for risk assess-
ment and risk management underpin international governance of the
blood supply in order to promote blood safety. However, risk is an
unstable concept and has been defined in varying ways. Risk assess-
ment has been viewed as the domain of scientific experts and risk
management as a matter for political leadership but the role of sci-
ence and politics in risk governance has been much debated: ‘In sim-
ple terms, there are those who view risk as an objective and knowable
phenomenon which can be measured, whereas for others it is socially
constructed and influenced by cultural, institutional and political
contexts’ (Farrell, 2012: 9). We take the view that risk is indeed a
socio-cultural construct shaped by political and wider institutional
processes. So the use of ‘classificatory technologies’ to identify
potential risks to the blood supply must be viewed as one of the ways
in which this dynamic operates.
Others have suggested that transplant medicine produces and rei-
fies biocultural categories of racial and ethnic difference through the
use of blood group and antigen human leucocyte antigen (HLA)
‘matching criteria’ for organ transplantation in ways that are discri-
minatory and perpetuate social inequalities (Kierans and Cooper,
2011). We suggest that similar processes are operating within trans-
fusion science and that valuations of bodily materials are variable
and gendered. As we will highlight, women’s bodies are constructed
as more ‘risky’ in a number of ways by national blood services, such
as in relation to the use of female plasma for transfusion and in the
manufacture of the blood product, known as Anti-D Ig. In both cases,
male bodies are more highly valued in terms of the source material
they provide for such blood components and products.
The collection and supply of blood for use in the production of a
range of components and plasma products has now become a com-
plex undertaking for national blood services (see Figure 1). On the
one hand, it is characterised by enduring socio-cultural and political
concerns about preferred methods of collection in line with national
preferences, which most often crystallises as support for the gift
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relationship in western bioeconomies. On the other hand, such con-
cerns must be managed in the context of interconnectedness both
within and across national boundaries, in relation to collection and
supply (Waldby and Mitchell, 2006). This shifts over time and space
in the face of emerging risks to blood safety, as well as in relation
to changing market demands for blood components and plasma prod-
ucts. Further layers of complexity are added to the mix because collec-
tion and manufacturing practices differ between blood components or
plasma products, and both for-profit and not-for-profit organisations
are involved in such practices:
Figure 1. Fresh blood components and plasma-derived and recombinant
products.
Source: www.blood.gov.au/about-blood
Kent and Farrell 35
when we talk about blood products and plasma products, they’re very
different. When you talk about a labile blood product that’s going to
be mainly used for transfusion purposes and when you talk about a
plasma product which is basically a product which is a finished phar-
maceutical, it’s a product that has undergone a manufacturing cycle,
it’s a stable product. So it’ll have much longer shelf-life and they are
products that circulate on the international level, whereas labile blood
products tend to be products that have much shorter shelf-life that are
used on a national scale. So that’s one of the key differences. Another
difference, I would say lies with collection practices, for both blood
and plasma products. Blood products, obviously they come from
blood donations made by blood donors. Plasma products, most of the
plasma products used on a global scale come from plasmapharesis
donors. So these are people who actually donate the plasma but not
the whole blood. They go to specialised plasmapharesis centres
[ . . . this] accounts for approximately 70 percent of the plasma that
is used for therapeutic purposes on a global scale. And then the 30 per-
cent of the remaining plasma comes from plasma that has been recov-
ered from blood donation. (Int. 16, Executive of an international
patient organisation)
In the UK, blood donation policy and the use of plasma products
has been shaped by concerns about the potential risks of transmission
of the prion disease vCJD. As we explain, plasma obtained frommale
whole blood donors may be used to produce fresh frozen plasma
(FFP) for transfusion in adults but no British plasma is used to man-
ufacture plasma products. As a consequence many plasma products
and tons of plasma for use in UK plasma product manufacture are
imported.2 It is a policy that is regarded as ‘silly’ by another respon-
dent who saw blood and plasma donation in Europe differently:
Most European countries get their plasma from volunteer non-
remunerated donors. [ . . . ] And there’s no way you can get a safe
plasma supply if you pay the donors and unfortunately Britain is now
importing plasma in the hundreds of thousands, hundreds of tons,
from plasma donors in the US, which is a disgrace. There’s no other
word for it. And you are undermining the self-sufficiency of Europe
because of your, I have to say, silly rules, about not using British
plasma. (Int. 14, International donor organisation)
The principle of national self-sufficiency in blood supply and
plasma products has been considered an important way of maximising
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blood safety but, as this plasma manufacturer explained, manufactur-
ing processes have advanced and plasma products are: ‘Very safe.
Very safe. In terms of viral transmission . . . [and] in terms of infec-
tivity the products are very, very safe’ (Int. 27, Plasma manufacturer).
He described how the US donor management programmes enhance the
safety profile of sourced plasma within the global industry. With
respect to the prevention of transmission of the prion implicated in
vCJD, his view was that: ‘The technology for removing those is only
just being developed’ and would need to be suitable for use in large-
scale manufacturing processes. Therefore, governing risk in blood ser-
vices and the plasma industry poses technical challenges but also
raises ethical and political concerns. The commonly expressed view
above (typical in Europe) is that paying donors increases the potential
threats to blood safety and is unethical. Moral issues are deeply
entwined with constructions of risk and safety.
While many national blood services are founded on voluntary
unremunerated donation, closer analysis of the literature reveals
how, within transfusion science and blood policies, categories
of donor and recipient bodies construct moral hierarchies and
scales of exchange and use value which have excluded MSM and
migrants as donors, and segregated blood along racial lines in
some countries (Bekker and Wood, 2006; Martucci, 2010; Starr,
1998; Valentine, 2005). Polonsky et al. say:
In some instances the gifting of blood offers a way for citizens to lit-
erally become a part of their nation, imagine a link between country-
men who could be ‘blood brothers’ and to feel socially included and
part of the political process. (2011: 337)
Interestingly, while attending to the exclusion of migrant peoples
and their citizenship status, Polonsky et al. fail to recognise the gen-
dered notion of citizenship operating here. For example, in societies
where marriage is the key source of status and security for women,
those who are carriers of thalassemia are marginalised and socially
excluded (Chattopadhyay, 2006). In these contexts, women’s repro-
ductive role continues to be associated with social exclusion and
marginalisation, rendering them as ‘not quite citizens’. Other studies
have highlighted the gendering of blood donation. In Brazil, only a
third of donors are women and donation is understood as a form of
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‘bloodletting’ for those who use hormone contraceptives to suppress
menstruation (Sanabria, 2009). In Pakistan, women’s blood is
regarded as ‘impure’ and they are not expected to donate blood
except when no men are available (Mumtaz et al., 2012). Experi-
ences of blood donation are gendered too. Blood may be seen both
as self and as alienable and rendered ‘non-self’ following manipula-
tion and transfusion. The notion that blood becomes anonymised and
‘just a product’:
was a distinctly masculine idea among the regular blood donors. Eight
out of nine male blood donors used some version of this model to
understand what they were doing when they gave blood, whereas the
female donors, with the exception of the nurse, were more inclined to
think of their blood as forming a relationshipwith the recipient, either
as a kind of loan or as a shared substance (Waldby et al., 2004: 1468,
emphasis added)
Our evidence indicates that women are constructed as different
kinds of donors and patient-recipients in relation to the assessment
of risk within this blood economy. As we describe below, the gender
identity of blood travels with it to the processing centre, and the
maternal body represents a threat to blood and plasma product safety.
Plasma – A Global Business
In the UK, blood collection is organised through four national blood
services based on unpaid, anonymised, voluntary donation. Along-
side this collection of whole blood there is a global plasma products
industry. Plasma product manufacturers obtain plasma from both
source companies, as well as ‘recovered’ plasma from whole blood
collected by blood services and hospitals (Figure 1). Plasma products
are exported around the world for the treatment of diverse medical
conditions. Much of the plasma is collected in the US from paid indi-
viduals but there are a number of countries, such as those in the Ben-
elux region, which operate on a not-for-profit basis, sourcing plasma
from voluntary, non-remunerated donors.
Demand for plasma and plasma-derived products is on the
increase, with one estimate putting global demand for plasma for
fractionation (Figure 1) at 41.7 million litres by 2015 (O’Mahony and
Turner, 2010: 447). Plasma supply is price sensitive and maintaining
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the supply of plasma donors (and blood donors) is a key priority for
both national governments and the industry. In the UK, plasma is
sourced from the US for use in fractionation since the exclusion of
all UK donors for the production of plasma products over ten years
ago. However, supplies of FFP are obtained from whole blood dona-
tions within the UK blood services.
For the most part, unlike state-sponsored blood services, which
emphasise the ethics of voluntarism and altruism, the for-profit
plasma products industry has not made claims to universality or
social citizenship in soliciting plasma donations. Indeed, the predo-
minantly US-based industry has traditionally relied on the socio-
economically disadvantaged or marginalised to provide plasma on
a regular basis in return for cash. While historically women’s plasma
has been valued where they carry high titres of RhD antibodies which
can be used in the manufacture of Anti-D Ig, the industry has shown
a long standing preference for male plasma, targeting prisoners,
inmates in mental institutions and gay men for antibodies needed
to manufacture particular products, such as gamma globulin and the
hepatitis B vaccine (Starr, 1998). Donor compliance and reducing
‘risky behaviour’ is at the heart of plasma procurement practices
today. There are industry standards which apply to the procure-
ment, processing and manufacturing of plasma which are intended
to reduce the risk of transmissible infections and viral disease, and
improve the quality and safety of the product (Farrell, 2012). Vol-
untary standards have been developed through the International
Quality Plasma Programme and, in Europe, the sourcing of plasma
must comply with the European Blood Directive.3 There has also
been more stringent oversight at national and supranational level
to ensure compliance with manufacturing standards within the
scope of international pharmaceutical (medicinal products) regula-
tion (Farrell, 2012).
What we want to draw attention to here is that plasma technologies
and products are inscribed with gender, that the technologies of risk
calculation are not neutral but are socially embedded. The continuing
debate about the risks attributed to MSM, and their exclusion as
blood (and tissue) donors since the HIV crisis, has drawn attention
to the contingent and discriminatory practices associated with the
risk calculus involving blood safety (Galarneau, 2010; Hoeyer,
2010). Within transfusion science, blood relations and exchanges are
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seen by Strong as creating ‘vital publics’ which are ‘embodied asso-
ciations elicited through the generalized exchange of body – in this
case blood. Participation in the vital public might therefore be seen
as a unique duty associated with the biological citizen’ (Strong,
2009: 173). He argues that exclusions of MSM as donors relied on
technologies which first sought to measure risk, then model it mathe-
matically. Yet the assessment of the risk of transfusing transmitted
viral infection is problematic, and socially relative, serving the politi-
cal ends of sustaining the blood supply and protecting public health.
As a consequence, we suggest that policies which mobilise particular
understandings of the potential risks of using plasma from women
must also be viewed in this light. Although women are recruited as
whole blood donors, their donations have different exchange value
to those of men.
Women Donors – Different but Equal?
Despite the appearance of the universality of blood donation, from
2003 all the UK blood services introduced a policy of ‘male donor
preference’, which involved women’s plasma being discarded fol-
lowing whole blood collection unless a shortage of male donor sup-
ply required stocks to be supplemented. The policy was based on the
view that data relating to the incidence of TRALI were linked to
transfusion with plasma from women (Chapman, 2011). This poten-
tially fatal ‘syndrome’ has only been characterised and named over
the past 20 years and definitions of it have been the subject of inter-
national debate and discussion. The clinical symptoms of breathless-
ness, hypoxia and pulmonary changes are associated with other
causes of lung trauma, making definition and diagnosis difficult
(Chapman et al., 2009), and pathogenesis of TRALI is poorly under-
stood (Shaz et al., 2011). One theory put forward is that it is related to
the interaction between donor HLA antibodies and leucocytes of the
patient but patient factors may also be significant. There is no spe-
cific diagnostic test for TRALI.
Nevertheless, since 1996, the UK haemovigliance scheme, Serious
Hazards of Transfusion (SHOT), has recorded reports of TRALI. In
2003, based on recommendations by SHOT, the National Blood Ser-
vice (NBS) decided to exclude the use of female plasma for the pro-
duction of FFP and suspension of buffy coat derived pooled platelets
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as far as possible, as part of their ‘risk reduction strategy’ (Chapman
and Williamson, 2008). In 1999, SHOT introduced a set of four cate-
gories of TRALI cases indicating the level of uncertainty about the
diagnosis: highly likely, probable, possible and unlikely. Each year,
therefore, a high proportion of reported TRALI cases are cate-
gorised as possible or unlikely to be TRALI. A ‘consensus confer-
ence’ in Canada in 2004 described the clinical criteria of ‘TRALI’
and ‘possible TRALI’. It is the presence of antibodies in female
plasma which was believed to be ‘implicated’ in the cause of TRALI.
HLA antibody production is in turn associated with pregnancy in
women.4
Despite the clinical and technical uncertainties surrounding the
definition and diagnosis of TRALI, the association with HLA
antibody-positive female donors led to this new policy and opera-
tional strategy in the following way:
Since new donor questions were being introduced regarding West
Nile virus and severe acute respiratory syndrome, it was agreed that
no additional questions would be asked regarding previous pregnancy
or transfusion. As a result of the option appraisal, the NBS introduced
in October 2003 a policy to use male plasma for manufacture of FFP
as far as was operationally possible. This policy did not involve any
additional donor questioning or loss of any donors from either whole
blood or apheresis collections, since plasma is not collected by the lat-
ter method. Fractionation of UK plasma was discontinued in 1999
because of vCJD, so all plasma from non-FFP donations is discarded.
(Chapman et al., 2009: 443)
Being female was therefore defined as a risk factor, in a similar
way to potential prion transmission from donors. Allwomen, whether
they had a history of pregnancy or not, were, as a result of this new
policy, deemed unfit (or at least undesirable) for plasma donation.
From this time onwards, whole blood donations were labelled ‘M’
or ‘F’ at the donor session for easy identification at the processing
centre. Since 2010, 100 percent of FFP has been produced from
recovered male plasma in the UK (NHS Blood and Transplant,
2012). At its largest national blood processing centre, female plasma,
once it is separated from the red blood cells at the first stage of pro-
cessing, is redirected to the ‘discard’ section to be sent for incinera-
tion. Risk factors are associated, not with reproductive history per se,
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but with reproductive potential, materialising female bodies as inher-
ently ‘risky’ sources of plasma.
It has been suggested that this ‘rather crude approach’ to the exclu-
sion of female plasma was ‘simple and low cost to implement’
(Chapman et al., 2009: 449). Moreover, because of the changes to
policy relating to fractionation of UK plasma in the wake of vCJD:
‘male FFP’ could be implemented without loss of any donors and
without the need to discuss the policy with the company undertaking
fractionation. Donors were already aware that plasma from most
donations was discarded and we have not specifically communicated
the male plasma policy to them. Similarly, the decision to suspend
most BC-derived PLT [buffy-coat-derived pooled platelet concen-
trates] pools in male plasma could be implemented relatively easily.
(Chapman et al., 2009: 449)
Although all female plasma was to be discarded at the first stage of
processing following donation, it was not considered necessary by
UK blood services to inform women donors that this was to take
place. This appears to have been rationalised on the basis that the ser-
vices did not want to adversely affect their willingness to donate
blood. This presumes that some women might decide not donate
blood if they knew that all their plasma was discarded and that
women have no entitlement to such information.
In addition, due to exclusion policies relating to vCJD risk, FFP for
patients born after 1996 in the UK has been imported since 2004
from male donors in the US, so these patients are not transfused with
UK plasma.5 Products derived from plasma pools are also expected
to be derived from male donors known as ‘Donor 1’. Hence staff
at the processing centre we visited referred to the ‘superior’ qualities
of male plasma and men who donate. In short, the change in UK pol-
icy appeared to raise no political concerns and, because it was easily
implemented alongside other restrictions relating to the use of UK
plasma, it received no public attention. From the point of view of
UK blood services, it was easy to discard female plasma and this was
seen as neither wasteful nor deserving of wider public justification or
explanation.
In information provided to donors, NHS Blood and Transplant
explains how plasma is used but does not make it clear either that
no plasma from UK donors is used in fractionation or that its ‘male
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preference policy’ operates in a way where women’s plasma is sel-
dom used at all:
Once separated from blood cells, plasma for patient use goes in one of
two directions. It can be used for blood transfusion as fresh frozen
plasma and other transfused plasma products. It can also be directed
to a plasma fractionation plant to undergo a more complicated type of
processing to separate out its many individual proteins.6
Such a statement lacks transparency and appears to deliberately
obscure practices within the UK blood services regarding the use
of plasma, and the use of female plasma in particular.
Under the cloak of changes which recognised that UK donors were
implicated as at risk of transmitting vCJD, and therefore their plasma
had limited exchange value, the specific gendering of policy relating
to plasma processing was effectively obscured. Unlike the discrimi-
nation against MSM, this policy exclusion of women’s plasma was
invisible for, though appearing to treat female donors as equal to
male donors, exclusion criteria operated after donation, at the stage
of processing blood donations. In short, it serves to perpetuate the
myth of universality even though in reality only certain ‘extractions’
from women are retained for use in transfusion. Women’s bioavail-
ability was considered jeopardised by their potential to become preg-
nant, which, in turn, could increase antibody production. In the
circumstances, FFP and other pooled platelet suspensions are now
highly gendered productions in the UK and elsewhere.
Strategies to prevent TRALI have been implemented in diverse
ways in other countries, based on differing interpretations of the evi-
dence of the link with female donor plasma. In Australia, for exam-
ple, the Australian Red Cross Blood Service now has a policy to use
predominantly male-only plasma for fresh plasma products. In its
publicly available Factsheet, it cites the UK experience as the evi-
dence base, while also acknowledging scientific uncertainty about
the causes of TRALI (Australian Red Cross Blood Service, 2012).
In the US, account is taken of both the diverse causes of TRALI
(Chapman, 2011) and scientific uncertainties surrounding the syn-
drome. US proposals highlight the need for a ‘partial, incremental
approach in making policy decisions’ and suggested ‘a plasma diver-
sion strategy’, which diverted female plasma for fractionation and
used male plasma for transfusion, but which sought to avoid
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alienating and confusing female donors (Eder et al., 2007). In
Canada, a combination of preference for male plasma transfusion and
high-volume plasma components, and screening of women who have
a history of pregnancy, has been thought to improve transfusion out-
comes (Lin et al., 2012).
Such measures have been designed to retain women donors while
also adopting a risk reduction strategy. Yet one study suggested that
cardiac patients who received female plasma transfusion had better
outcomes and that excluding female plasma donors could have detri-
mental effects (Welsby et al., 2010). Others argued that evidence
supported female donor screening and exclusion (Shaz et al.,
2011). Paradoxically, while the gender identity of FFP is considered
important in relation to TRALI, in a recent study of the use of FFP in
England which questioned its clinical benefits, no data on the gender
of patients receiving it were collected (Stanworth et al., 2011; Yang
et al., 2012).
In sum, men and women are viewed as very different kinds of
donors within transfusion science. Women may be regarded as poten-
tially risky plasma donors, due to their antibody status, which is pre-
sumed in the blanket exclusion of female plasma wherever possible
in the UK. Women are neither routinely screened nor tested for their
antibody status. This contrasts with other western countries which
use a different approach, one that redirects rather than discards
female plasma, or screens women donors for their pregnancy history.
Maternal bodies and maternity are represented as a potential threat to
the safety of the plasma supply.
Women Recipients of Anti-D Ig
So far we have considered the gendering of donation; the gendering
of transfusion practices, however, extends to women as recipients of
blood and plasma products, particularly in the obstetric context.
More specifically, the implications of pregnancy for women’s need
for transfusion or plasma products, as well as their status as blood
or plasma donors, is a defining feature of blood relations. This is the
case not only for those who become pregnant, have a miscarriage or
abortion, but for all women. What is of interest here is the treatment
of a relatively small group of women who are blood type RhD neg-
ative (an estimated 16% in the white UK population; NICE, 2008;
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Pilgrim et al., 2009), which has wider significance for how women
are positioned within the blood economy.
In pregnancy, where the woman is RhD negative and the fetus is
RhD positive, if fetal maternal haemorrhage occurs where fetal cells
cross the placenta, it may stimulate antibody production which can
cause Rh HDFN, a potentially fatal blood disorder (NHS Blood and
Transplant, 2010). The production of HLA antibodies by the woman,
known as sensitisation, may have particularly serious consequences
for subsequent pregnancies, and therefore the administration of a
plasma product, Anti-D Ig, is designed to prevent sensitisation and
antibody production. Anti-D Ig can be administered prophylactically
antenatally or postnatally or following any sensitising event which
may have caused fetal maternal haemorrhage (this might include
miscarriage, abortion, or intrauterine testing and trauma). Although
Anti-D Ig has been used as a prophylactic treatment for over 40 years
in many western countries (Kumpel, 2001, 2002; Kumpel and Elson,
2001), the mechanism of this passive immunisation is poorly under-
stood and the efficacy of different treatments has not been well stud-
ied (Pilgrim et al., 2009). Nevertheless, it is considered to have been
highly successful in reducing the incidence of HDFN. Paternal blood
group testing may assist in identifying those women at risk of becom-
ing sensitised. A new technology for antenatal testing involving cell
free fetal DNA (cffDNA), which circulates in the maternal blood
(genotyping), has the potential to identify the blood group of the fetus
and therefore determine whether there is a need for prophylactic
administration (Brojer et al., 2005; NICE, 2008). To date, this test
has not become widely available for ‘at risk’ women. However, there
are risks for women associated with the use of Anti-D Ig and its
incorrect administration, and many women receive this product
unnecessarily (Bolton-Maggs et al., 2013; Finning et al., 2008; Kent
et al., 2014).
In Ireland, between 1977 and 1994, large numbers of women were
infected with hepatitis C (HCV) as a result of receiving contaminated
Anti-D Ig product manufactured by the Blood Transfusion Service
Board (BTSB), which ran the national blood service at the time. The
Anti-D Ig in question had been sourced from two female Irish donors
who had received plasma exchange treatment. The BTSB was com-
mitted to achieving national self-sufficiency in blood and plasma
products and failed to withdraw the products even after those in
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charge of the service became aware that various batches were likely
to have been contaminated with hepatitis. Following the introduction
of testing on all blood donations for HCV in the early 1990s, cases
involving women blood donors who were HCV-positive emerged,
leading to an investigation which revealed the extent of HCV con-
tamination of Anti-D Ig.
A high-profile political scandal followed. Positive Action, a sup-
port group for women affected by the contamination, successfully
lobbied the government for a comprehensive health care package,
and for a tribunal to be established to award financial compensation
for the harm they had suffered (Positive Action, 2012). The Irish gov-
ernment also convened a Tribunal of Inquiry, which found that there
had been a clear contravention of policy guidelines in relation to both
the way in which blood was collected as source material for Anti-D
Ig and the protocols used in the manufacture of the product by the
BTSB (Tribunal of Inquiry, 1997: 148). A programme to trace and
identify all the women who received HCV-contaminated Anti-D Ig
found that 1089 women were HCV antibody positive, of whom
503 are positive on polymerase chain reaction testing with viral type
consistent with infection through Anti-D Ig (Irish Blood Transfusion
Service, 2012). The Irish case highlighted the consequences of viral
transmission through plasma products at a time when new technolo-
gies for viral testing were emerging, and the vulnerability of pregnant
women receiving Anti-D Ig therapy.
The Use of Anti-D Ig in the UK
The use of Anti-D Ig in the UK today raises complex safety issues
and risks for women related to its misuse and the product itself. In
2011, 249 adverse events involving administration of the product
were reported to SHOT (SHOT, 2011). Sixty women received
Anti-D Ig when they should not have been given it, while in 157
cases it was omitted or given later than recommended. As one inter-
viewee noted:
A very good friend of mine is a midwife and she regularly administers
Anti-D. I asked her do you understand that this is a pooled blood prod-
uct and if one of your patients asked you what are the risks would you
know? She didn’t. (Int. 2, Government adviser)
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More recently, administration of Anti-D Ig has become a target for
training of midwives and will shortly be the subject of a national
audit in the UK. Although there are no direct health benefits to
women from routine administration of Anti-D Ig, and despite some
criticism (Wickham, 2001), the prevention of HDFN remains a pri-
ority and justification for its use (Harkness, 2012; Harkness et al.,
2008; NICE, 2008). However, current UK guidelines recommend
that all RhD negative women should be offered prophylactic Anti-
D Ig, which means that those who carry a RhD negative fetus
(approximately 40,000 women per year) receive this product unne-
cessarily (Finning et al., 2008).
Anti-D Ig is commercially produced, has a very large market and
the costs to health services of routine antenatal Anti-D prophylaxis
are high (NICE, 2008). Since administration of Anti-D Ig became
routine, the numbers of sensitised women whose blood may be used
as source material for the product has been reduced, Anti-D Ig
is currently commercially produced from predominantly male
bodies. Male plasma donors, who are well known to the source
company and have well characterised plasma, constitute a pool
from which potential Anti-D donors are selected.7 They are paid
a premium to receive repeated doses of RhD positive red blood
cells to stimulate an immune response to produce antibodies
which can then be harvested at the next plasma donation.
Anti-D Ig is then manufactured from pooled plasma from these
men for use in women. (It may also be used infrequently in cases
where RhD negative men are wrongly transfused with RhD pos-
itive blood.)
This procedure is unusual in a number of respects for it is the only
active intervention in the body of a male plasma donor to stimulate
antibody production. Second, it attracts a market premium and is tied
in to a scheme of incentives for men who donate plasma which is
unavailable to paid women donors, unless they are ‘older’ and
post-menopausal (though few of these are used).8 The higher price
paid for this plasma reflects potential risks to the male donor but also
the higher value placed on their bodily products. Women who pro-
duce these antibodies naturally (as a result of pregnancy) are
excluded and women of reproductive age are regarded at high risk
of sensitisation which could adversely impact on future pregnancies.
The technology to produce monoclonal (synthetic) Anti-D Ig has
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been developed, but is not currently commercially viable (Kumpel,
2001, 2002; Interview 27).
What is revealed here is how transactions between men and women
are technologically mediated. These technologies are embedded
within a gendered blood economy where male bodies are sourced for
plasma and plasma proteins and the production of commercially avail-
able Anti-D Ig, shaped by an immuno-politics which merits closer
analysis.
Maternity and the Immune System
Transfusion science draws on a set of rationalities about the immune
system which have emerged within a specifically gendered historical
context (Haraway, 1995). The biomedical body was conventionally
seen to represent the nation-state and invading organisms as foreign-
ers. More recently, scientific and cultural understandings see the
immune system as a complex networked system (Martin, 1994).
Within this framework, maternal bodies, in particular, are often rep-
resented as paradoxical and explanations about why the genetically
distinct fetus is not rejected by the mother have provoked consider-
able debate and stimulated a long history of investigation. In preg-
nancy the fetal and maternal circulations have increasingly been
understood as closely interconnected. Maternal fetal microchimerism
refers to the mixing of cells from the maternal and fetal body (Kelly,
2012; Martin, 2010) and placental ‘border crossings’ which may pro-
voke an immunological response. Kelly’s (2012) account of the
emergence of gestational cell transfer science and understandings
of maternal–fetal microchimerism reveals the extent of scientific
uncertainty about the significance and meaning of these exchanges.
While previously thought to be pathological, fetal cells entering the
maternal circulation have more recently been considered normal.
Biology has intrinsically been a branch of political discourse
which constructs and constitutes political subjects (Kelly, 2012: 5).
Immunology theory supported and reinforced a set of political val-
ues about normal and pathological states, subjectivity and identity.
The fetus was thought of as a hostile ‘invader’ or ‘intruder’ and the
placenta as a barrier between two separate selves (Martin, 1994).
The dominant view was that the immune system ‘defends the self’
and the pure body is the normal body (Kelly, 2012). With
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recognition that cells routinely cross the placental interface, a rela-
tional model of the immune system begins to emerge, as a complex,
dynamic network (Haraway, 1995). Instead of a barrier, the pla-
centa may be viewed as a permeable interface where exchanges
between mother and fetus occur in both directions – ‘bidirectional
cell trafficking’ (Martin, 2010). The discovery of the intermingling
of maternal and fetal circulations and blood type incompatibility as
a cause of HDFN in the 1960s was important in developing Anti-D
Ig therapy. The implications of a revised model of the immune sys-
tem – as relational and networked – are much wider. First, the
notion that all bodies are chimeric undermines notions of the modern
political subject as a distinct individual (Kelly, 2012); second, it
implies a different way of thinking about antibodies, and their signifi-
cance for transfusion practices starts to seem far more complex than a
blanket exclusion of women as plasma donors in the UK suggests. Yet,
in the context of transfusion science, it is presumed that the immune
status of (all) women is compromised because of their potential expo-
sure to a fetal body, thereby affecting their suitability to become
plasma donors. In contrast, the commercial production of Anti-D Ig
by injecting male RhD negative plasma donors’ with RhD positive
cells to produce antibodies, is an accepted and valued practice.
Conclusion
Our reading of the UK ‘male preference policy’ for plasma is that it is
discriminatory. It constructs all women as risky plasma donors regard-
less of their age, reproductive history or antibody status. Implemented
with no public consultation or discussion, there is a continuing lack of
public information or explanation of this policy. This in turn raises
questions about the ethics of donation – the information given to
women about becoming blood donors. While retaining women donors
in the donor pool may be an important policy objective, the different
ways in which their donations are processed is information which
should be made available. The myths of universality, citizenship and
solidarity should be publicly elaborated upon to explain and justify the
ways in which women are treated as different kinds of donors from
men. As we have shown, women are unable to donate blood as fre-
quently as men; all women’s plasma is likely to be discarded in the
UK; and elsewhere its use is limited to processing for fractionation.
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We have also shown that Anti-D Ig is produced mainly from male
bodies for use in pregnant and parturient women. Women of repro-
ductive age are usually excluded from becoming donors for the prod-
uct or having access to additional payments for such donations.
Moreover, many women receive Anti-D Ig when it is unnecessary
(Kent et al., 2014). In short, the institutional arrangements for plasma
collection and processing favour ‘Donor 1’ men. Practices around
procurement and distribution render gender differences both invisi-
ble and visible. Patient information describes Anti-D Ig as produced
from ‘specially selected donors’ (NHS Blood and Transplant, 2010)
and women are often unaware that they may not need Anti-D Ig if
they are carrying an RhD negative fetus. Plasma products are not
simply homogeneous, neutral, universal technologies – rather gender
is inscribed upon them. Gender difference is produced within the
industry and blood services.
Technologies of risk assessment are also not neutral. The calcu-
lation of risk associated with FFP plasma transfusion rests on lim-
ited understandings of the causes or characterisation of TRALI and
an evidence base which includes a wide-ranging categorisation of
‘highly likely, probably, possible, unlikely’ cases. Transfusion sci-
ence, as a discourse of truth and power, is tied to technological
change and emergent forms of knowledge and expertise. In creating
categories of donors, donor deferral policies, screening, testing and
matching policies, it ‘governs life’ through the exercise of bio-
power. Women’s position is tied to their reproductive work and
their reproductive potential within an increasingly globalised and
commercial blood economy (Busby et al., 2013), in circumstances
where the policy rationale for such positioning remains unclear and
lacks transparency.
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Notes
1. ESRC Project RES-062-23-2751. Ethical approval for the study was
given by an NHS REC.
2. The sale of Plasma Resources UK in July 2013 to Bain Capital has been
especially controversial (see: https://www.gov.uk/government/news/
minister-welcomes-bain-capital-buying-majority-stake -in-pruk; http://
www.opendemocracy.net/ournhs/lucy-reynolds/selling-our-safety-to-
highest-bidder-privatisation-of-plasma-resources-uk).
3. See: http://www.pptaglobal.org; Directive 2002/98/EC setting standards
of quality and safety for the collection, testing, processing, storage and
distribution of human blood and blood components and amending
Directive 2001/83/EC OJ L 33.
4. Multiparous women are more likely to have high levels of antibodies
(Chapman, 2011).
5. Joint UKBTS/NIBSC Professional Advisory Committee (2007) Position
statement: Creutzfeldt-Jakob Disease. SHOT Report (2003: 63).
6. See: NHS Blood and Transplant ‘How blood is used’, http://www.blood.
co.uk/about-blood/how-blood-is-used/plasma (accessed August
2013).
7. Men who have been previously transfused are excluded.
8. See advertising for RhD negative plasma donors – by Cangene Plasma,
Biotest which recruits women and men; women must be surgically ster-
ile or post-menopausal.
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